In general, Women are prescribed more drugs than men and have an approximately 1.5 times higher risk of developing ADRs than men. ADR reported to the pharmacovigilance programme are analysed to explore new scientific information. Women are thought to be more at risk for ADRs. This study was aimed to analyse the cardiovascular drugs showing preponderance of adverse effects in female patients. The details of drugs selected for our study were filtered from Vigibase and the results were interpreted. Captopril, enalapril, losartan, valsartan, candesartam, aliskiren, lidocaine, bosentan, ambrisentan, macitentan, icantibant, verapamil, adenosine, propanolol, atenolol, metaprolol, labetalol amlodipine, nifedipene are the drugs which showed female preponderance of Adverse effects. Many drugs are known to produce more ADRs in female patients. Future studies are needed to explore pharmacokinetic and pharmacodynamic mechanisms causing more ADRs in females.
Loading....